title: Adjuvant bevacizumab in colon cancer: where did we go wrong?
authors.affiliation: Section of Oncology and Clinical Research, Leeds Institute of Molecular Medicine, University of Leeds, Leeds LS9 7TF, UK. m.seymour@ncrn.org.uk
authors.forename: Matthew T
authors.initials: MT
authors.lastname: Seymour
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D003110:Colonic Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D000077150:Oxaliplatin
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068258:Bevacizumab